Published in Clin Cancer Res on May 30, 2013
HMGB1 in health and disease. Mol Aspects Med (2014) 1.67
Inflammatory Response After Laparoscopic Versus Open Resection of Colorectal Liver Metastases: Data From the Oslo-CoMet Trial. Medicine (Baltimore) (2015) 1.41
Strange attractors: DAMPs and autophagy link tumor cell death and immunity. Cell Death Dis (2013) 1.25
Emerging role of high-mobility group box 1 (HMGB1) in liver diseases. Mol Med (2013) 1.17
Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia. Blood (2014) 1.15
Hypoxia induced HMGB1 and mitochondrial DNA interactions mediate tumor growth in hepatocellular carcinoma through Toll-like receptor 9. J Hepatol (2015) 1.05
Interplay between ROS and autophagy in cancer cells, from tumor initiation to cancer therapy. Redox Biol (2014) 1.04
MIR34A regulates autophagy and apoptosis by targeting HMGB1 in the retinoblastoma cell. Autophagy (2014) 0.99
Targeting autophagy in breast cancer. World J Clin Oncol (2014) 0.99
Neutrophil Extracellular Traps Promote the Development and Progression of Liver Metastases after Surgical Stress. Cancer Res (2016) 0.97
Topoisomerase IIα in chromosome instability and personalized cancer therapy. Oncogene (2014) 0.97
HMGB1, IL-1α, IL-33 and S100 proteins: dual-function alarmins. Cell Mol Immunol (2016) 0.89
Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer. Front Immunol (2015) 0.89
Expression of RAGE and HMGB1 in thymic epithelial tumors, thymic hyperplasia and regular thymic morphology. PLoS One (2014) 0.89
The Role of HMGB1 Signaling Pathway in the Development and Progression of Hepatocellular Carcinoma: A Review. Int J Mol Sci (2015) 0.88
Oxidative stress-mediated HMGB1 biology. Front Physiol (2015) 0.87
Cell death and DAMPs in acute pancreatitis. Mol Med (2014) 0.86
Increased HMGB1 and cleaved caspase-3 stimulate the proliferation of tumor cells and are correlated with the poor prognosis in colorectal cancer. J Exp Clin Cancer Res (2015) 0.86
p53-Regulated Networks of Protein, mRNA, miRNA, and lncRNA Expression Revealed by Integrated Pulsed Stable Isotope Labeling With Amino Acids in Cell Culture (pSILAC) and Next Generation Sequencing (NGS) Analyses. Mol Cell Proteomics (2015) 0.86
Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment. Neuro Oncol (2016) 0.85
Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy. Oncoimmunology (2015) 0.85
Mechanisms of therapeutic resistance in cancer (stem) cells with emphasis on thyroid cancer cells. Front Endocrinol (Lausanne) (2014) 0.85
High-Mobility Group Box 1 Promotes Hepatocellular Carcinoma Progression through miR-21-Mediated Matrix Metalloproteinase Activity. Cancer Res (2015) 0.84
High mobility group box 1 (HMGB1) phenotypic role revealed with stress. Mol Med (2014) 0.83
Knockdown of HMGB1 improves apoptosis and suppresses proliferation and invasion of glioma cells. Chin J Cancer Res (2014) 0.83
High mobility group box-1 and its clinical value in breast cancer. Onco Targets Ther (2015) 0.83
CREB-induced inflammation is important for malignant mesothelioma growth. Am J Pathol (2014) 0.82
NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies: New Hints for NK-Based Immunotherapy? J Immunol Res (2016) 0.81
DAMPs, ageing, and cancer: The 'DAMP Hypothesis'. Ageing Res Rev (2014) 0.81
Novel concepts on pregnancy clocks and alarms: redundancy and synergy in human parturition. Hum Reprod Update (2016) 0.81
HMGB1-DNA complex-induced autophagy limits AIM2 inflammasome activation through RAGE. Biochem Biophys Res Commun (2014) 0.80
Structure-Based Analysis Reveals Cancer Missense Mutations Target Protein Interaction Interfaces. PLoS One (2016) 0.80
HMGB1 overexpression as a prognostic factor for survival in cancer: a meta-analysis and systematic review. Oncotarget (2016) 0.79
High-mobility group box 1 potentiates antineutrophil cytoplasmic antibody-inducing neutrophil extracellular traps formation. Arthritis Res Ther (2016) 0.79
High Mobility Group B Proteins, Their Partners, and Other Redox Sensors in Ovarian and Prostate Cancer. Oxid Med Cell Longev (2015) 0.79
Failure of anti tumor-derived endothelial cell immunotherapy depends on augmentation of tumor hypoxia. Oncotarget (2014) 0.79
Circulating HMGB1 and RAGE as Clinical Biomarkers in Malignant and Autoimmune Diseases. Diagnostics (Basel) (2015) 0.79
Different Toll-Like Receptor Expression Patterns in Progression toward Cancer. Front Immunol (2014) 0.78
Emodin inhibits HMGB1-induced tumor angiogenesis in human osteosarcoma by regulating SIRT1. Int J Clin Exp Med (2015) 0.78
Autophagy-mediated HMGB1 release promotes gastric cancer cell survival via RAGE activation of extracellular signal-regulated kinases 1/2. Oncol Rep (2015) 0.78
Until Death Do Us Part: Necrosis and Oxidation Promote the Tumor Microenvironment. Transfus Med Hemother (2016) 0.78
Carbon-ion beams induce production of an immune mediator protein, high mobility group box 1, at levels comparable with X-ray irradiation. J Radiat Res (2015) 0.78
HMGB1 induction of clusterin creates a chemoresistant niche in human prostate tumor cells. Sci Rep (2015) 0.78
MiR-218 inhibits HMGB1-mediated autophagy in endometrial carcinoma cells during chemotherapy. Int J Clin Exp Pathol (2015) 0.78
PGE2 induced in and released by dying cells functions as an inhibitory DAMP. Proc Natl Acad Sci U S A (2016) 0.77
Integrated transcriptional profiling and genomic analyses reveal RPN2 and HMGB1 as promising biomarkers in colorectal cancer. Cell Biosci (2015) 0.77
Local and systemic RAGE axis changes in pulmonary hypertension: CTEPH and iPAH. PLoS One (2014) 0.77
Relationship between high-mobility group box 1 overexpression in ovarian cancer tissue and serum: a meta-analysis. Onco Targets Ther (2015) 0.77
Directional migration of adult hematopoeitic progenitors to C6 glioma in vitro. Oncol Lett (2015) 0.77
PPAR Ligands Function as Suppressors That Target Biological Actions of HMGB1. PPAR Res (2016) 0.77
High Mobility Group Box-1 Promotes Inflammation-Induced Lymphangiogenesis via Toll-Like Receptor 4-Dependent Signalling Pathway. PLoS One (2016) 0.77
Role of Redox Status in Development of Glioblastoma. Front Immunol (2016) 0.77
Hijacker of the Antitumor Immune Response: Autophagy Is Showing Its Worst Facet. Front Oncol (2016) 0.76
The association of HMGB1 expression with clinicopathological significance and prognosis in Asian patients with colorectal carcinoma: a meta-analysis and literature review. Onco Targets Ther (2016) 0.76
Emerging roles for HMGB1 protein in immunity, inflammation, and cancer. Immunotargets Ther (2015) 0.76
Leukocytes recruited by tumor-derived HMGB1 sustain peritoneal carcinomatosis. Oncoimmunology (2016) 0.76
Poly-ADP-ribosylation of HMGB1 regulates TNFSF10/TRAIL resistance through autophagy. Autophagy (2015) 0.76
Triple helix-interacting proteins and cancer. OA Mol Oncol (2013) 0.76
Paradoxical Role of High Mobility Group Box 1 in Glioma: A Suppressor or a Promoter? Oncol Rev (2017) 0.76
Emerging role of HMGB1 in lung diseases: friend or foe. J Cell Mol Med (2016) 0.75
Lycorine Downregulates HMGB1 to Inhibit Autophagy and Enhances Bortezomib Activity in Multiple Myeloma. Theranostics (2016) 0.75
Histone H1 Differentially Inhibits DNA Bending by Reduced and Oxidized HMGB1 Protein. PLoS One (2015) 0.75
Involvement of HMGB1 in Resistance to Tumor Vessel-Targeted, Monoclonal Antibody-Based Immunotherapy. J Immunol Res (2016) 0.75
HMGB1 Induces Secretion of Matrix Vesicles by Macrophages to Enhance Ectopic Mineralization. PLoS One (2016) 0.75
High mobility group protein 1: A collaborator in nucleosome dynamics and estrogen-responsive gene expression. World J Biol Chem (2016) 0.75
Serum HMGB1 as a Potential Biomarker for Patients with Asbestos-Related Diseases. Dis Markers (2017) 0.75
Krüppel-like factor 4 promotes high-mobility group box 1-induced chemotherapy resistance in osteosarcoma cells. Cancer Sci (2016) 0.75
Tumor-released autophagosomes induce IL-10-producing B cells with suppressive activity on T lymphocytes via TLR2-MyD88-NF-κB signal pathway. Oncoimmunology (2016) 0.75
Immunosuppressive cell death in cancer. Nat Rev Immunol (2017) 0.75
Secreted HMGB1 from Wnt activated intestinal cells is required to maintain a crypt progenitor phenotype. Oncotarget (2016) 0.75
Hypoxia mediates mitochondrial biogenesis in hepatocellular carcinoma to promote tumor growth via HMGB1 and TLR9 interaction. Hepatology (2017) 0.75
High Mobility Group Box Protein 1 Boosts Endothelial Albumin Transcytosis through the RAGE/Src/Caveolin-1 Pathway. Sci Rep (2016) 0.75
High-mobility group protein box1 expression correlates with peritumoral macrophage infiltration and unfavorable prognosis in patients with hepatocellular carcinoma and cirrhosis. BMC Cancer (2016) 0.75
Innate immunity and hepatocarcinoma: Can toll-like receptors open the door to oncogenesis? World J Hepatol (2016) 0.75
Clinical Value of High Mobility Group Box 1 and the Receptor for Advanced Glycation End-products in Head and Neck Cancer: A Systematic Review. Int Arch Otorhinolaryngol (2016) 0.75
Novel chemokine-like activities of histones in tumor metastasis. Oncotarget (2016) 0.75
Intracellular HMGB1 as a novel tumor suppressor of pancreatic cancer. Cell Res (2017) 0.75
CBP501 suppresses macrophage induced cancer stem cell like features and metastases. Oncotarget (2017) 0.75
The dual role and therapeutic potential of high-mobility group box 1 in cancer. Oncotarget (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature (2002) 19.77
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90
A role for mitochondria in NLRP3 inflammasome activation. Nature (2010) 13.21
Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell (2006) 11.79
High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol (2005) 11.57
Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol (2007) 8.33
Autophagy suppresses tumor progression by limiting chromosomal instability. Genes Dev (2007) 7.41
The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med (2005) 6.86
Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature (2000) 6.70
Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J (2003) 6.46
HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol (2011) 6.23
Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer (2012) 6.14
HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol (2010) 5.65
Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science (2011) 5.62
The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem (1995) 5.36
CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science (2009) 5.00
The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep (2002) 4.76
Endogenous HMGB1 regulates autophagy. J Cell Biol (2010) 4.71
Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity (2008) 4.37
A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci U S A (2010) 3.80
Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol (2012) 3.57
Role of HMGB1 in apoptosis-mediated sepsis lethality. J Exp Med (2006) 3.26
High-mobility group box 1 and cancer. Biochim Biophys Acta (2010) 3.11
Autophagy-based unconventional secretory pathway for extracellular delivery of IL-1β. EMBO J (2011) 3.04
HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene (2010) 2.91
The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol (2006) 2.90
Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med (2012) 2.89
HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells. Leukemia (2010) 2.83
HMGB1 promotes drug resistance in osteosarcoma. Cancer Res (2011) 2.82
HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med (2009) 2.56
RAGE signaling sustains inflammation and promotes tumor development. J Exp Med (2008) 2.51
A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J (2007) 2.44
Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins. Nature (1999) 2.35
HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J Exp Med (2012) 2.35
The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ (2009) 2.30
Substantial histone reduction modulates genomewide nucleosomal occupancy and global transcriptional output. PLoS Biol (2011) 2.26
PAMPs and DAMPs: signal 0s that spur autophagy and immunity. Immunol Rev (2012) 2.24
High-mobility group box 1, oxidative stress, and disease. Antioxid Redox Signal (2011) 2.19
Hydrogen peroxide stimulates macrophages and monocytes to actively release HMGB1. J Leukoc Biol (2006) 2.17
High-mobility group box 1 is essential for mitochondrial quality control. Cell Metab (2011) 1.89
Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol (2002) 1.82
Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Res (2002) 1.63
Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res (2011) 1.62
Priming the nucleosome: a role for HMGB proteins? EMBO Rep (2003) 1.62
Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res (2012) 1.61
Activation of poly(ADP)-ribose polymerase (PARP-1) induces release of the pro-inflammatory mediator HMGB1 from the nucleus. J Biol Chem (2007) 1.51
The HMGB1/RAGE inflammatory pathway promotes pancreatic tumor growth by regulating mitochondrial bioenergetics. Oncogene (2013) 1.43
High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases. Hepatology (2012) 1.42
p53/HMGB1 complexes regulate autophagy and apoptosis. Cancer Res (2012) 1.41
Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma. Cancer Res (2012) 1.40
TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells. EMBO J (2010) 1.37
Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1. Oncogene (2012) 1.37
The expression of the receptor for advanced glycation endproducts (RAGE) is permissive for early pancreatic neoplasia. Proc Natl Acad Sci U S A (2012) 1.30
Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomas. Virchows Arch (2005) 1.27
Yeast Nhp6A/B and mammalian Hmgb1 facilitate the maintenance of genome stability. Curr Biol (2005) 1.24
HMGB1: a two-headed signal regulating tumor progression and immunity. Curr Opin Immunol (2008) 1.21
HMGB1: the jack-of-all-trades protein is a master DNA repair mechanic. Mol Carcinog (2009) 1.20
Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system. Nat Med (2012) 1.19
Hypoxia-increased RAGE and P2X7R expression regulates tumor cell invasion through phosphorylation of Erk1/2 and Akt and nuclear translocation of NF-{kappa}B. Carcinogenesis (2011) 1.17
Growth suppression and radiosensitivity increase by HMGB1 in breast cancer. Acta Pharmacol Sin (2007) 1.15
A dual role for UVRAG in maintaining chromosomal stability independent of autophagy. Dev Cell (2012) 1.13
Rage signalling promotes intestinal tumourigenesis. Oncogene (2012) 1.11
PKR-dependent inflammatory signals. Sci Signal (2012) 1.07
High mobility group box 1 released from necrotic cells enhances regrowth and metastasis of cancer cells that have survived chemotherapy. Eur J Cancer (2012) 1.06
Ethyl pyruvate administration inhibits hepatic tumor growth. J Leukoc Biol (2009) 1.04
Knockdown of HMGB1 in tumor cells attenuates their ability to induce regulatory T cells and uncovers naturally acquired CD8 T cell-dependent antitumor immunity. J Immunol (2011) 1.04
The expression of receptor for advanced glycation end products is associated with angiogenesis in human oral squamous cell carcinoma. Virchows Arch (2007) 1.03
High mobility group protein B1 is an activator of apoptotic response to antimetabolite drugs. Mol Pharmacol (2007) 1.00
Bif-1 haploinsufficiency promotes chromosomal instability and accelerates Myc-driven lymphomagenesis via suppression of mitophagy. Blood (2013) 1.00
HMGB1-facilitated p53 DNA binding occurs via HMG-Box/p53 transactivation domain interaction, regulated by the acidic tail. Structure (2012) 0.99
Suppression of dendritic cells by HMGB1 is associated with lymph node metastasis of human colon cancer. Pathobiology (2009) 0.98
Tissue damage-associated "danger signals" influence T-cell responses that promote the progression of preneoplasia to cancer. Cancer Res (2012) 0.95
HMGB1 and HMGB2 proteins up-regulate cellular expression of human topoisomerase IIalpha. Nucleic Acids Res (2009) 0.92
HMGB1 gene knockout in mouse embryonic fibroblasts results in reduced telomerase activity and telomere dysfunction. Chromosoma (2012) 0.88
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med (2005) 6.86
Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res (2011) 5.40
Interleukin-17 promotes angiogenesis and tumor growth. Blood (2002) 4.90
Endogenous HMGB1 regulates autophagy. J Cell Biol (2010) 4.71
Robot-assisted minimally invasive distal pancreatectomy is superior to the laparoscopic technique. Ann Surg (2013) 3.94
Inflammation and necrosis promote tumour growth. Nat Rev Immunol (2004) 3.68
The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev (2007) 3.33
High-mobility group box 1 and cancer. Biochim Biophys Acta (2010) 3.11
IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol (2005) 3.02
Interleukin-12: biological properties and clinical application. Clin Cancer Res (2007) 3.00
HMGB1 promotes drug resistance in osteosarcoma. Cancer Res (2011) 2.82
Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol (2007) 2.81
Hepatic ischemia/reperfusion injury involves functional TLR4 signaling in nonparenchymal cells. J Immunol (2005) 2.78
RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med (2009) 2.56
Masquerader: high mobility group box-1 and cancer. Clin Cancer Res (2007) 2.40
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov (2013) 2.29
PAMPs and DAMPs: signal 0s that spur autophagy and immunity. Immunol Rev (2012) 2.24
High-mobility group box 1, oxidative stress, and disease. Antioxid Redox Signal (2011) 2.19
Systemic inflammation and remote organ injury following trauma require HMGB1. Am J Physiol Regul Integr Comp Physiol (2007) 2.12
Serum biomarker panels for the detection of pancreatic cancer. Clin Cancer Res (2011) 1.98
Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1. Proc Natl Acad Sci U S A (2009) 1.94
Interleukin-1F7B (IL-1H4/IL-1F7) is processed by caspase-1 and mature IL-1F7B binds to the IL-18 receptor but does not induce IFN-gamma production. Cytokine (2002) 1.92
High-mobility group box 1 is essential for mitochondrial quality control. Cell Metab (2011) 1.89
Addicted to death: invasive cancer and the immune response to unscheduled cell death. J Immunother (2004) 1.88
Robotic-assisted major pancreatic resection and reconstruction. Arch Surg (2010) 1.82
Second-generation tetracycline-regulatable promoter: repositioned tet operator elements optimize transactivator synergy while shorter minimal promoter offers tight basal leakiness. J Gene Med (2004) 1.80
Autophagy inhibition in combination cancer treatment. Curr Opin Investig Drugs (2009) 1.79
Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci U S A (2010) 1.72
Cancer and inflammation: promise for biologic therapy. J Immunother (2010) 1.72
Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer (2010) 1.70
UV irradiation resistance-associated gene suppresses apoptosis by interfering with BAX activation. EMBO Rep (2011) 1.68
Arginine and immunity. J Nutr (2007) 1.62
Feature Selection for Classification of SELDI-TOF-MS Proteomic Profiles. Appl Bioinformatics (2005) 1.56
Multivisceral resection does not affect morbidity and survival after cytoreductive surgery and chemoperfusion for carcinomatosis from colorectal cancer. Ann Surg Oncol (2008) 1.52
Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer. Ann Surg Oncol (2010) 1.48
Autophagy regulates myeloid cell differentiation by p62/SQSTM1-mediated degradation of PML-RARα oncoprotein. Autophagy (2011) 1.47
NF-κB hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells. Cancer Res (2012) 1.46
Interleukin-17 enhances bFGF-, HGF- and VEGF-induced growth of vascular endothelial cells. Immunol Lett (2004) 1.46
Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma. Ann Surg Oncol (2013) 1.46
High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J Immunother (2007) 1.45
Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis. J Leukoc Biol (2009) 1.45
Meta-analysis of APOE4 allele and outcome after traumatic brain injury. J Neurotrauma (2008) 1.44
High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases. Hepatology (2012) 1.42
Cutting edge: high-mobility group box 1 preconditioning protects against liver ischemia-reperfusion injury. J Immunol (2006) 1.42
Complementary dendritic cell-activating function of CD8+ and CD4+ T cells: helper role of CD8+ T cells in the development of T helper type 1 responses. J Exp Med (2002) 1.41
p53/HMGB1 complexes regulate autophagy and apoptosis. Cancer Res (2012) 1.41
Eosinophilic granulocytes and damage-associated molecular pattern molecules (DAMPs): role in the inflammatory response within tumors. J Immunother (2007) 1.39
Monocytes promote natural killer cell interferon gamma production in response to the endogenous danger signal HMGB1. Mol Immunol (2005) 1.39
The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res (2005) 1.34
Quercetin prevents LPS-induced high-mobility group box 1 release and proinflammatory function. Am J Respir Cell Mol Biol (2009) 1.32
Receptor-mediated signalling in plants: molecular patterns and programmes. J Exp Bot (2009) 1.31
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med (2009) 1.31
Interleukin-17 augments tumor necrosis factor-alpha-induced elaboration of proangiogenic factors from fibroblasts. Immunol Lett (2004) 1.30
EUS-guided fiducial placement for stereotactic body radiotherapy in locally advanced and recurrent pancreatic cancer. Gastrointest Endosc (2010) 1.30
HMGB1: a novel Beclin 1-binding protein active in autophagy. Autophagy (2010) 1.30
The expression of the receptor for advanced glycation endproducts (RAGE) is permissive for early pancreatic neoplasia. Proc Natl Acad Sci U S A (2012) 1.30
Increasing numbers of hepatic dendritic cells promote HMGB1-mediated ischemia-reperfusion injury. J Leukoc Biol (2006) 1.27
High mobility group box 1 (HMGB1) activates an autophagic response to oxidative stress. Antioxid Redox Signal (2011) 1.27
Dealing with death: HMGB1 as a novel target for cancer therapy. Curr Opin Investig Drugs (2003) 1.24
Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. J Surg Oncol (2013) 1.24
250 robotic pancreatic resections: safety and feasibility. Ann Surg (2013) 1.23
A Janus tale of two active high mobility group box 1 (HMGB1) redox states. Mol Med (2012) 1.21
Cell-mediated autophagy promotes cancer cell survival. Cancer Res (2012) 1.21
Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center. Ann Surg Oncol (2007) 1.21
Damage associated molecular pattern molecules. Clin Immunol (2007) 1.19
Targeting HMGB1-mediated autophagy as a novel therapeutic strategy for osteosarcoma. Autophagy (2012) 1.19
HMGB1: The Central Cytokine for All Lymphoid Cells. Front Immunol (2013) 1.18
Inhibiting systemic autophagy during interleukin 2 immunotherapy promotes long-term tumor regression. Cancer Res (2012) 1.17
Cytolytic cells induce HMGB1 release from melanoma cell lines. J Leukoc Biol (2006) 1.14
Integration of KRAS testing in the diagnosis of pancreatic cystic lesions: a clinical experience of 618 pancreatic cysts. Mod Pathol (2013) 1.12
Aggressive management of peritoneal carcinomatosis from mucinous appendiceal neoplasms. Ann Surg Oncol (2012) 1.12
Eat-me: autophagy, phagocytosis, and reactive oxygen species signaling. Antioxid Redox Signal (2012) 1.11
Natural killer-dendritic cell cross-talk in cancer immunotherapy. Expert Opin Biol Ther (2005) 1.11
DAMP-mediated autophagy contributes to drug resistance. Autophagy (2011) 1.10